Mirum Pharmaceuticals, Inc. MIRM AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s AFS securities?
- Mirum Pharmaceuticals, Inc. (MIRM) reported AFS securities of $34.35M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s AFS securities changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s AFS securities increased by 64.3% year-over-year, from $20.91M to $34.35M.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.